Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Growth stagnated in the first half of 2019. Management says it will be temporary.

Here's Why Illumina Tumbled 18.7% in July

Are the disappointing results for Illumina a "new normal"? Not at all, according to its top executives.

5 Things Illumina's Management Just Said That You'll Really Want to Know

The genomic sequencing company reported slower revenue growth because of several issues, including a delay in closing a major population genomics deal.

Illumina Hits a Speed Bump in the 2nd Quarter

Illumina Hits a Speed Bump in the Second Quarter

Illumina Inc. ILMN, +1.17% shares declined in the extended session Monday after the genetics technology company's revenue and outlook fell short of Wall Street expectations.

Illumina stock declines after earnings, outlook

Illumina on Monday reported adjusted earnings of $1.35 per share on $838 million in sales for its second quarter ended June 30. Illumina's guidance for adjusted earnings in 2019 was light.

Genomics Behemoth Dips On Mixed Report; 2019 Profit Guidance Light

Illumina (NASDAQ: ILMN) releases its next round of earnings this Monday, July 29.

Q2 Earnings Preview For Illumina

Abbott Labs

Baxter

Becton, Dickinson and Co.

Boston Scientific

Edwards Lifesciences

Intuitive Surgical

Johnson & Johnson

Medtronic

Stryker

Market caps for these medical device stocks are big. Most of them have been big winners, too.

10 Biggest Medical Device Stocks

On 7/11, Illumina announce preliminary Q2 revenues. The company announced low Q2 revenue and cut its 2019 revenue guidance.

Illumina: The Sequencing King Is Now On Sale

Illumina is set to report its Q2 earnings on Monday, July 29 and investors are waiting to see if there is anything that might help the stock recover from its recent fall.

What to Expect from Illumina Earnings After Preliminary Results Tanked ILMN Stock

Illumina (ILMN) is expected to deliver a strong second quarter on impressive performance by sequencing portfolio.

Can Sequencing Products Drive Illumina's (ILMN) Q2 Earnings?

Pacific Biosciences of California

Abandoning the proposed deal would have a seismic effect on the future of DNA sequencing, but it's not all bad news for investors.

What Happens If Pacific Biosciences Isn't Acquired By Illumina?

Illumina warned of a revenue shortfall

Block

Aurora Cannabis

Square, Johnson & Johnson, Illumina, Canopy Growth and Aurora Cannabis are our top stock trades for Monday.

4 Top Stock Trades for Monday: JNJ, SQ, ILMN, ACB

These healthcare stocks are breaking down on the charts. Investors should be careful before stepping into these four.

4 Healthcare Stocks That Are Feeling Sick  

EMCORE

Hillenbrand

US Xpress Enterprises

US Xpress Enterprises, Illumina, Hillenbrand and EMCORE decline on important news.

4 Stocks Tank Friday

Illumina Inc. (NASDAQ: ILMN) shares dropped on Friday after the firm announced a preliminary revenue miss and a 50% cut to its 2019 revenue growth guidance.

Why Canaccord Genuity Is on the Sideline About Illumina

Illumina news for Friday concerning early results for the second quarter of 2019 that are below estimates is hitting ILMN stock hard.
The post Illumina News: Why ILMN Stock Is Plummeting appeared first on InvestorPlace.

Illumina News: Why ILMN Stock Is Plummeting

Shares of Illumina plunged 16% after the genetic sequencing company reported its preliminary revenue estimates for the second quarter.

Illumina's Revenue Falls Short

Weak preliminary Q2 results are weighing heavily on the genomic sequencing specialist.

Why Illumina Stock Is Tanking Today

Illumina crashed Friday after the genomics company preannounced a $52 million shortfall in second-quarter sales. Illumina cited slower direct-to-consumer and government initiative sales.

This Genomics Stock Just Lost A Breakout — Why Analysts Still Like It

DNA sequencing and array-based technologies company Illumina, Inc. (NASDAQ: ILMN) pre-announced second-quarter results Thursday that represent a "big miss" versus expectations, according to Bank of America Merrill Lynch.

BofA Double Downgrades Illumina After Thursday's 'Big Miss'

The Dow Jones industrials and the S&P 500 set more record highs early Friday. Illumina stock plunged after a revenue warning.

Dow Jones Hits Record Highs To Lead Stock Market Rally; Illumina Plunges

Shares of Illumina Inc. ILMN, -14.88% plummeted 16% in active morning trading Friday, after Bank of America Merrill Lynch swung to being bearish from bullish in the wake of the genetics company's revenue warning.

Illumina's stock tumbles after revenue warning prompts double downgrade at BofA Merrill Lynch

Illumina Inc (NASDAQ: ILMN) shares are trading lower after the company reported preliminary second-quarter sales below analyst estimates.

News for Illumina Stock (ILMN)